longer under the EU Clinical Trials Regulation (CTR), UK pharmacovigilance obligations are harmonised with EU and global standards, ensuring UK trial data remain internationally acceptable.

Core Pharmacovigilance Obligations in UK Clinical Development

1. SAE and SUSAR Reporting

Investigators must report all SAEs to sponsors within 24 hours. Sponsors assess causality and expectedness against the Reference Safety Information (RSI). If an SAE qualifies as a SUSAR:

• Fatal or life-threatening SUSARs must be reported to MHRA within 7 days, with follow-up information submitted within 8 days.
• All other SUSARs must be reported within 15 days.

2. Reporting to RECs and Investigators

Sponsors must inform RECs and all investigators of SUSARs. Safety letters and summaries are expected to ensure trial-wide awareness.

3. Development Safety Update Report (DSUR)

Annual DSURs must be submitted to MHRA and RECs, providing cumulative safety data, risk-benefit assessment, and emerging safety concerns. DSURs follow ICH E2F format.

4. Urgent Safety Measures (USMs)

When an immediate hazard is identified, sponsors may implement urgent safety measures. Notification to MHRA and REC is required within 3 days, with justification and corrective actions.

5. Safety Oversight Systems

Sponsors must maintain validated pharmacovigilance databases, ensure CRO oversight where applicable, and appoint a Qualified Person for Pharmacovigilance (QPPV) or equivalent for oversight.

6. Transparency and Public Disclosure

Safety reporting obligations include transparency under HRA requirements, ensuring results—including safety outcomes—are published within 12 months of trial completion.

7. Inspection Readiness

MHRA GCP inspections frequently highlight PV deficiencies such as:

• Delayed SUSAR submissions
• Poor SAE documentation at sites
• Incomplete DSUR data
• Weak CRO oversight
• Lack of TMF documentation for safety activities

Best Practices and Preventive Measures

• Train investigators on SAE reporting requirements and timelines.
• Establish clear SAE reporting workflows and escalation pathways.
• Validate pharmacovigilance systems and maintain audit trails.
• Implement dashboards to track SUSAR timelines in real time.
• Conduct internal audits to verify DSUR accuracy and completeness.

Scientific and Regulatory Evidence

• Medicines for Human Use (Clinical Trials) Regulations 2004 (as amended)
• MHRA Pharmacovigilance Guidance
• ICH E2A – Clinical Safety Data Management
• ICH E2F – Development Safety Update Report
• ICH E6(R2) – Good Clinical Practice

Special Considerations

• Pediatric Trials: Safety reporting must include caregiver observations and child-specific endpoints.
• Rare Diseases: Safety signals may be harder to interpret due to small sample sizes, requiring enhanced vigilance.
• Advanced Therapies: ATMPs demand long-term follow-up reporting, often beyond the trial close-out date.
• Decentralised Trials: Digital tools must be validated for accurate, timely AE reporting.

When Sponsors Should Seek Regulatory Advice

• If unsure whether an event qualifies as a SUSAR.
• When implementing digital pharmacovigilance tools.
• For complex ATMP, pediatric, or rare disease trials.
• If MHRA inspections reveal pharmacovigilance gaps.
• When developing urgent safety measures requiring expedited implementation.

FAQs

1. What are SUSAR reporting timelines in the UK?

Fatal or life-threatening SUSARs: 7 days (with follow-up in 8 days). All other SUSARs: 15 days.

2. What is a DSUR?

The Development Safety Update Report is an annual cumulative safety report required for all UK clinical trials.

3. Who is responsible for pharmacovigilance compliance?

The sponsor, though CROs may assist. The sponsor remains ultimately accountable to MHRA.

4. What happens if SUSARs are reported late?

MHRA may issue inspection findings, request CAPAs, or suspend trial activity.

5. Do decentralized trials change PV obligations?

Obligations remain the same, but digital systems must be validated to ensure compliance.

6. Are academic sponsors held to the same PV standards?

Yes. Universities and NHS Trusts sponsoring trials must comply with MHRA pharmacovigilance requirements.

7. How does HRA ensure PV transparency?

HRA requires trial results, including safety outcomes, to be disclosed within 12 months of trial completion.

Conclusion

Pharmacovigilance obligations in the UK clinical trial context are strict, comprehensive, and non-negotiable. Sponsors must establish robust systems for SAE/SUSAR reporting, DSUR submission, urgent safety measures, and oversight of CROs. By aligning with MHRA, HRA, and international standards, sponsors can ensure participant safety, regulatory compliance, and inspection readiness throughout clinical development.